EBV and CMV peptide-specific cytotoxicity in HIV-infected and healthy donors requires perforin expression on tetramer-positive CD8 T cells: direct testing of whole PBMCs
| Subject . | HIV status . | Tetramer . | Tetramer-positive cells . | Specific cytotoxicity at E/T ratio, % . | ||||
|---|---|---|---|---|---|---|---|---|
| CD8 T cells, % . | Perforin+, % . | 200:1 . | 100:1 . | 50:1 . | 25:1 . | |||
| 307 | Seropositive | A2 CMV | 0.96 | 25.0 | 7 | 3 | 0 | — |
| 501 | Seropositive | A2 CMV | 2.47 | 35.0 | — | 30* | 11* | 7* |
| CW16 | Seropositive | A2 EBV | 0.76 | 71.0 | — | 2 | 2 | 0 |
| CW20 | Seropositive | B8 EBV | 1.04 | 0.0 | 0 | 0 | 2 | 0 |
| HD1 | Seronegative | A2 CMV | 4.1 | 82.0 | 25* | 12* | 7* | — |
| HD2 | Seronegative | A2 CMV | 0.59 | 2.5 | 0.3 | 0 | 0 | — |
| HD3 | Seronegative | A2 EBV | 0.05 | 0.0 | 0 | 0 | 0 | — |
| Subject . | HIV status . | Tetramer . | Tetramer-positive cells . | Specific cytotoxicity at E/T ratio, % . | ||||
|---|---|---|---|---|---|---|---|---|
| CD8 T cells, % . | Perforin+, % . | 200:1 . | 100:1 . | 50:1 . | 25:1 . | |||
| 307 | Seropositive | A2 CMV | 0.96 | 25.0 | 7 | 3 | 0 | — |
| 501 | Seropositive | A2 CMV | 2.47 | 35.0 | — | 30* | 11* | 7* |
| CW16 | Seropositive | A2 EBV | 0.76 | 71.0 | — | 2 | 2 | 0 |
| CW20 | Seropositive | B8 EBV | 1.04 | 0.0 | 0 | 0 | 2 | 0 |
| HD1 | Seronegative | A2 CMV | 4.1 | 82.0 | 25* | 12* | 7* | — |
| HD2 | Seronegative | A2 CMV | 0.59 | 2.5 | 0.3 | 0 | 0 | — |
| HD3 | Seronegative | A2 EBV | 0.05 | 0.0 | 0 | 0 | 0 | — |
PBMCs were tested directly for cytotoxicity against autologous B-cell lines incubated with tetrameric peptide or media. The frequencies of tetramer-positive cells before and after selection are shown, together with the percentages of tetramer-positive cells that stain for perforin. *Percent specific cytotoxicity is greater than 5%.